Brief Articles
Copyright ©2009 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Aug 14, 2009; 15(30): 3793-3798
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3793
Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: A retrospective cohort study
Chang-Zheng Du, Wei-Cheng Xue, Yong Cai, Ming Li, Jin Gu
Chang-Zheng Du, Ming Li, Jin Gu, Department of Colorectal Surgery, Peking University School of Oncology, Beijing 100142, China
Wei-Cheng Xue, Department of Pathology, Peking University School of Oncology, Beijing 100142, China
Yong Cai, Department of Radiotherapy, Peking University School of Oncology, Beijing 100142, China
Author contributions: Du CZ performed research and wrote the paper; Xue WC made the pathologic evaluation of tumor specimens; Cai Y provided the consult and technical support for neoadjuvant radiotherapy; Li M and Gu J designed research and made critical revisions of the manuscript.
Correspondence to: Jin Gu, MD, FACS, Professor and Chairman of Colorectal Surgery, Peking University School of Oncology, 52 Fucheng Road, Haidian District, Beijing 100142, China. zlguj@yahoo.com.cn
Telephone: +86-10-88141032
Fax: +86-10-88141032
Received: May 10, 2009
Revised: July 2, 2009
Accepted: July 9, 2009
Published online: August 14, 2009
Abstract

AIM: To investigate the meaning of lymphovascular invasion (LVI) in rectal cancer after neoadjuvant radiotherapy.

METHODS: A total of 325 patients who underwent radical resection using total mesorectal excision (TME) from January 2000 to January 2005 in Beijing cancer hospital were included retrospectively, divided into a preoperative radiotherapy (PRT) group and a control group, according to whether or not they underwent preoperative radiation. Histological assessments of tumor specimens were made and the correlation of LVI and prognosis were evaluated by univariate and multivariate analysis.

RESULTS: The occurrence of LVI in the PRT and control groups was 21.4% and 26.1% respectively. In the control group, LVI was significantly associated with histological differentiation and pathologic TNM stage, whereas these associations were not observed in the PRT group. LVI was closely correlated to disease progression and 5-year overall survival (OS) in both groups. Among the patients with disease progression, LVI positive patients in the PRT group had a significantly longer median disease-free period (22.5 mo vs 11.5 mo, P = 0.023) and overall survival time (42.5 mo vs 26.5 mo, P = 0.035) compared to those in the control group, despite the fact that no significant difference in 5-year OS rate was observed (54.4% vs 48.3%, P = 0.137). Multivariate analysis showed the distance of tumor from the anal verge, pretreatment serum carcinoembryonic antigen level, pathologic TNM stage and LVI were the major factors affecting OS.

CONCLUSION: Neoadjuvant radiotherapy does not reduce LVI significantly; however, the prognostic meaning of LVI has changed. Patients with LVI may benefit from neoadjuvant radiotherapy.

Keywords: Lymphovascular invasion; Rectal cancer; Neoadjuvant radiotherapy; Total mesorectal excision; Pathology; Prognosis